Navigation Links
FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Date:9/20/2007

cell chronic lymphocytic leukemia (B-CLL) are diagnosed in the U.S. each year. It is the largest subset of chronic lymphocytic leukemia (CLL), the most common form of adult leukemia in the western world. B-CLL is characterized by the accumulation of functionally immature cells in the bone marrow, blood, lymph tissue and other organs. Because these cancerous B cells have a longer than normal life span, they begin to build up and "crowd out" normal, healthy blood cells and can become fatal. Symptoms include fatigue, bone pain, night sweats, fevers, and decreased appetite and weight loss. Bone marrow infiltration leads to a lack of healthy blood cells, thus causing susceptibility to bleedings and weakening of the immune system, exposing the patient to a higher risk of infection.

Additional Information About Campath

Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). Campath has a boxed warning which includes information on cytopenias, infusion reactions, and infections. The most commonly reported adverse reactions are infusion reactions (fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 9,500 employees in locations spanning the globe and 2006 revenues of $3.2 billion
'/>"/>

SOURCE Genzyme Corp. and Bayer HealthCare Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. UW Board of Regents approves $134 million medical research facility
7. FDA approves Bone Cares Hectorol for treatment of kidney disease
8. New Microarray Labeling Kit for Preparing cDNA Probes
9. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
10. aRNA Synthesis and Labeling for Array Analysis
11. Amino Allyl Labeling for Array Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... San Diego, CA (PRWEB) December 23, 2014 ... Contest where their Twitter followers can submit their ... for themselves and their lab mates. , For those ... beloved lab mates, the Pipette.com Holiday in the Lab ... encourages Pipette.com Twitter followers to send pictures ...
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy & ... it has signed a letter of intent to ... developed and patented a nanotechnology-based development platform used ... that enable rapid on-site collection and testing to ... health issues in an immediate, non-invasive and cost-effective ...
(Date:12/22/2014)... Fertility Associates of Memphis has announced ... , a network of more than 20 contributing ... have fast access to a national pool of frozen ... Fertility Associates of Memphis is the only fertility clinic ... , Dr. William Kutteh , director of Fertility ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3
... , , CAMBRIDGE, ... ), a biopharmaceutical company engaged in the discovery and development of ... pricing of an underwritten offering of 7,248,936 shares of its common ... and commissions and estimated offering expenses, the company expects to receive ...
... , , SAN DIEGO, Aug. 5 ... will provide partial funds for long-term follow-up testing of patients enrolled ... The funding will enable Ceregene to collect and analyze more ... Parkinson,s disease who were enrolled in the double-blind, controlled trial which ...
... Mass., Aug. 5 NxStage Medical, Inc. (Nasdaq: NXTM ... revenue for the second quarter of 2009 of $36.4 million, an ... for the second quarter of 2008. , , ... in Home, solid machine sales in Critical Care, and continued progress ...
Cached Biology Technology:Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock 2Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients 2Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients 3Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients 4NxStage Reports Second Quarter 2009 Financial Results 2NxStage Reports Second Quarter 2009 Financial Results 3NxStage Reports Second Quarter 2009 Financial Results 4NxStage Reports Second Quarter 2009 Financial Results 5NxStage Reports Second Quarter 2009 Financial Results 6NxStage Reports Second Quarter 2009 Financial Results 7NxStage Reports Second Quarter 2009 Financial Results 8NxStage Reports Second Quarter 2009 Financial Results 9NxStage Reports Second Quarter 2009 Financial Results 10NxStage Reports Second Quarter 2009 Financial Results 11NxStage Reports Second Quarter 2009 Financial Results 12
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
(Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... pleased to announce the 2010 Yeast Genetics and Molecular ... of British Columbia (UBC) in Vancouver, Canada. This ... eukaryotic biology in yeast. Program highlights include presentations ... is also a Member of Parliament. The ...
... discovered a key reason why a form of leukemia ... phase called blast crisis. The study, led by cancer ... G. James Cancer Hospital and Richard J. Solove Research ... when immature white blood cells lose a molecule called ...
... Diego, paleoceanographer Richard Norris is one of 41 scientists presenting ... and myriad other organisms 30 years after the theory was ... paper being released Friday in the journal Science ... the cause of the mass extinction. Norris, contribution to the ...
Cached Biology News:2010 Yeast Genetics and Molecular Biology Meeting 22010 Yeast Genetics and Molecular Biology Meeting 3Study identifies key cause of chronic leukemia progression 230 years later, what killed the dinosaurs is revisited 230 years later, what killed the dinosaurs is revisited 3
ImageQuant 100 UV, 1 EA. Category: ImageQuant CCD Imagers....
ImageQuant 300, 1 EA. Category: ImageQuant CCD Imagers....
Recombinant Feline IL-12/IL-23 p40...
RABBIT ANTI ISOCITRATE DEHYDROGENASE...
Biology Products: